Update 2016 – Immuntherapie beim Urothelkarzinom

M. Retz; J. E. Gschwend; S. C. Schmid

doi:10.1007/s00120-015-0024-y

Update 2016 – Immuntherapie beim Urothelkarzinom

Translated title of the contribution: Update 2016 – Immunotherapy for urothelial carcinoma

M. Retz
, J. E. Gschwend
, S. C. Schmid

Technical University of Munich

Research output: Contribution to journal › Article › peer-review

Abstract

Advanced urothelial carcinoma of the bladder is an aggressive tumor with a poor prognosis. Besides surgical therapy, classical chemotherapy with platinum compounds is the mainstay of advanced bladder cancer treatment. In recent years, immune modulating therapies have come into the focus of clinical trials. This review provides an overview of the biological mechanisms and immuno-oncological drugs that are currently being analyzed in clinical trials as well as established standard therapies.

Translated title of the contribution	Update 2016 – Immunotherapy for urothelial carcinoma
Original language	German
Pages (from-to)	246-252
Number of pages	7
Journal	Urologe - Ausgabe A
Volume	55
Issue number	2
DOIs	https://doi.org/10.1007/s00120-015-0024-y
State	Published - 1 Feb 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s00120-015-0024-y

Cite this

@article{cbf04a67ffe144289717a7990b6a74a2,

title = "Update 2016 – Immuntherapie beim Urothelkarzinom",

abstract = "Advanced urothelial carcinoma of the bladder is an aggressive tumor with a poor prognosis. Besides surgical therapy, classical chemotherapy with platinum compounds is the mainstay of advanced bladder cancer treatment. In recent years, immune modulating therapies have come into the focus of clinical trials. This review provides an overview of the biological mechanisms and immuno-oncological drugs that are currently being analyzed in clinical trials as well as established standard therapies.",

keywords = "Bladder cancer, Chemotherapy, Clinical trials, Immunotherapy, Urothelial cancer",

author = "M. Retz and Gschwend, \{J. E.\} and Schmid, \{S. C.\}",

note = "Publisher Copyright: {\textcopyright} 2015, Springer-Verlag Berlin Heidelberg.",

year = "2016",

month = feb,

day = "1",

doi = "10.1007/s00120-015-0024-y",

language = "Deutsch",

volume = "55",

pages = "246--252",

journal = "Urologe - Ausgabe A",

issn = "0340-2592",

publisher = "Springer Medizin",

number = "2",

}

TY - JOUR

T1 - Update 2016 – Immuntherapie beim Urothelkarzinom

AU - Retz, M.

AU - Gschwend, J. E.

AU - Schmid, S. C.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Advanced urothelial carcinoma of the bladder is an aggressive tumor with a poor prognosis. Besides surgical therapy, classical chemotherapy with platinum compounds is the mainstay of advanced bladder cancer treatment. In recent years, immune modulating therapies have come into the focus of clinical trials. This review provides an overview of the biological mechanisms and immuno-oncological drugs that are currently being analyzed in clinical trials as well as established standard therapies.

AB - Advanced urothelial carcinoma of the bladder is an aggressive tumor with a poor prognosis. Besides surgical therapy, classical chemotherapy with platinum compounds is the mainstay of advanced bladder cancer treatment. In recent years, immune modulating therapies have come into the focus of clinical trials. This review provides an overview of the biological mechanisms and immuno-oncological drugs that are currently being analyzed in clinical trials as well as established standard therapies.

KW - Bladder cancer

KW - Chemotherapy

KW - Clinical trials

KW - Immunotherapy

KW - Urothelial cancer

UR - https://www.scopus.com/pages/publications/84958107107

U2 - 10.1007/s00120-015-0024-y

DO - 10.1007/s00120-015-0024-y

M3 - Artikel

C2 - 26767648

AN - SCOPUS:84958107107

SN - 0340-2592

VL - 55

SP - 246

EP - 252

JO - Urologe - Ausgabe A

JF - Urologe - Ausgabe A

IS - 2

ER -

Update 2016 – Immuntherapie beim Urothelkarzinom

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this